Oral and maxillofacial surgery · 2025
Bone-formation-related markers in osteonecrosis of the jaws and their correlation with radiographic findings.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Schulz Riéli Elis, Wopereis Sandro, Schussel Juliana Lucena, Sassi Laurindo Moacir, Santos Aira Maria Bonfim, Grando Liliane Janete, Gondak Rogério Oliveira, Rabelo Gustavo Davi
Аннотация
PURPOSE: To evaluate serum levels of the bone-formation-related markers sclerostin and alkaline phosphatase (ALP) in patients with medication-related osteonecrosis of the jaw (MRONJ) and osteoradionecrosis (ORN), and to identify a correlation with radiographic findings.
METHODS: A cross-sectional study was conducted with osteonecrosis patients [MRONJ (n = 11); ORN (n = 21)] compared with individuals without osteometabolic diseases (control group, CG n = 27). Serum levels of sclerostin (pg/ml) and ALP (U/L) were evaluated. Gray-level pixel intensity (mean-Mgv and standard deviation-SDgv), fractal dimension (FD), and lacunarity (Lac) in the necrotic site (N), at the perinecrotic bone (PB), and in the non-lesional-bone site (CB) were assessed.
RESULTS: Higher sclerostin levels were observed in ORN (90, p = 0.04) and MRONJ (133, p < 0.01) vs. CG (45). ALP differed (p < 0.01) between MRONJ (60.2) and CG (79.3). All radiographic parameters revealed significant differences among the 3 sites (p < 0.05). A multivariate analysis showed an association of sclerostin with Mgv at N (p = 0.002) and Lac (p < 0.004) at CB, and an association of ALP with Mgv at N (p < 0.01), SDgv at PB (p < 0.01), and with sclerostin (p < 0.01).
CONCLUSIONS: Serum sclerostin levels were higher in patients with osteonecrosis. ALP levels were lower in MRONJ patients than in CG. Both proteins were associated with each other and with radiographic findings.
METHODS: A cross-sectional study was conducted with osteonecrosis patients [MRONJ (n = 11); ORN (n = 21)] compared with individuals without osteometabolic diseases (control group, CG n = 27). Serum levels of sclerostin (pg/ml) and ALP (U/L) were evaluated. Gray-level pixel intensity (mean-Mgv and standard deviation-SDgv), fractal dimension (FD), and lacunarity (Lac) in the necrotic site (N), at the perinecrotic bone (PB), and in the non-lesional-bone site (CB) were assessed.
RESULTS: Higher sclerostin levels were observed in ORN (90, p = 0.04) and MRONJ (133, p < 0.01) vs. CG (45). ALP differed (p < 0.01) between MRONJ (60.2) and CG (79.3). All radiographic parameters revealed significant differences among the 3 sites (p < 0.05). A multivariate analysis showed an association of sclerostin with Mgv at N (p = 0.002) and Lac (p < 0.004) at CB, and an association of ALP with Mgv at N (p < 0.01), SDgv at PB (p < 0.01), and with sclerostin (p < 0.01).
CONCLUSIONS: Serum sclerostin levels were higher in patients with osteonecrosis. ALP levels were lower in MRONJ patients than in CG. Both proteins were associated with each other and with radiographic findings.